CD69 Antagonists Inhibit T Cell Activation for Colitis Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies are inadequate for effectively treating inflammatory conditions such as colitis and hepatitis, which involve imbalanced immune responses and cytokine dysregulation, particularly with regards to T cell activation and CD69 expression.

Innovation Solution

Administering CD69 antagonists, including antibodies, aptamers, or small molecule pharmaceuticals, to inhibit CD69 activity, either alone or in combination with other therapies, to reduce the susceptibility and severity of inflammatory conditions like colitis and hepatitis.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional therapies are used to treat inflammatory conditions, then treatment is provided, but the therapies are inadequate for effectively treating inflammatory conditions such as colitis and hepatitis

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidsuitability for inflammatory conditions

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent changes the therapeutic parameter from conventional anti-inflammatory approaches to targeting CD69 expression specifically. By administering CD69 antagonists that block CD69-mediated T cell activation, the treatment addresses the root cause of inflammatory conditions through a novel mechanism, improving effectiveness where conventional therapies fail

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent introduces CD69 antagonists as intermediary substances that mediate between the immune system and inflammatory conditions. These antagonists specifically block CD69 protein function, preventing pathological T cell activation without broadly suppressing immunity, thereby providing effective treatment adapted to inflammatory conditions

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If T cell activation is increased to fight infection, then immune response is enhanced, but inflammatory conditions such as colitis and hepatitis worsen due to imbalanced immune responses

Engineering Contradiction:

Improveimmune response effectivenessVSAvoidinflammation and tissue damage

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality control by specifically targeting CD69 expression on activated T cells rather than broadly suppressing all immune activity. The CD69 antagonist selectively blocks pathological T cell activation in inflamed tissues while preserving normal immune functions, thereby enhancing immune response effectiveness where needed while reducing harmful inflammation

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent implements feedback control by targeting CD69, an early activation marker that provides real-time information about T cell activation status. By blocking CD69, the treatment creates negative feedback on pathological immune activation, preventing excessive inflammation while allowing appropriate immune responses to proceed

Inventive Principle:

Principle #23Feedback

Data Source

PatentUS10449252B2Inhibition of CD69 for treatment of inflammatory conditions

Publication Date: 2019.10.22 CHIBA UNIV

AI summary

A method of treating or reducing at least one inflammatory condition or the susceptibility to at least one inflammatory condition is provided involving administering at least one CD69 antagonist to a subject, wherein the subject has been diagnosed with at least one inflammatory condition, or a susceptibility to the same. CD69 antagonists can include one or more of an anti-CD69 antibody, an anti-CD69 aptamer, a CD69 mRNA antagonist, and a small molecule pharmaceutical.